Jonathan Edelman, senior vice president of CSL’s vaccines innovation unit, said the approval “marks a significant milestone” ...
Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today ...
The European Commission has granted marketing authorization for Kostaive (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, ...
The first sa-mRNA vaccine to reach any market was Gennova Biopharmaceuticals' Gemcovac, which was launched in India in 2022 ...
KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional ...
CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that the European Commission has granted marketing authorization for Kostaive, a ...
CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that the European Commission has granted marketing authorization for Kostaive, a ...
The centralized marketing authorization of KOSTAIVE is valid in all EU member states and in the EEA countries. "The European Commission's approval marks a significant milestone in our ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results